PepEvolutionHGH Fragment 176-191
AOD parent fragment
The C-terminal GH fragment behind AOD-9604, lipolytic in animal models, very thin human evidence.
Verdict, D · Speculative
Plausible lipolytic mechanism in animals, but thin human evidence and no clinical development program. Moderate gray-market availability and a reasonable safety profile don't compensate for the weak evidence base. D-grade.
Overview
HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal region of human growth hormone, proposed to retain the lipolytic activity of native GH without IGF-1-mediated growth effects. Most supporting data are from rodent studies or in-vitro; human evidence is sparse and largely anecdotal. It is the parent peptide of AOD-9604, which underwent a formal failed phase-2b obesity trial.
PepScore Breakdown, the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version?, our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI, see methodology.
Want a clinical path?
Talk to a licensed provider about HGH Fragment 176-191 and whether it's appropriate for your situation.
Talk to a Provider ↗Telehealth. Not medical advice, for educational purposes.
Get the PepEvolution Dispatch
Monthly COA findings, vendor changes, and new grades. Research/educational only, no spam.
Educational only, not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links, this never affects grades. Consult a licensed healthcare provider before using any compound.